Production (Stage)
Edgewise Therapeutics, Inc.
EWTX
$15.29
-$0.13-0.84%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | -40.80M | -39.66M | -34.13M | -31.50M | -28.53M |
Total Depreciation and Amortization | 554.00K | 629.00K | 602.00K | 534.00K | 525.00K |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 7.14M | 5.14M | 3.64M | 1.67M | 1.72M |
Change in Net Operating Assets | -4.76M | 6.94M | 2.51M | 3.19M | -2.32M |
Cash from Operations | -37.87M | -26.96M | -27.37M | -26.10M | -28.60M |
Capital Expenditure | -44.00K | -274.00K | -520.00K | -221.00K | -297.00K |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 43.94M | 21.20M | 25.88M | 37.59M | -268.01M |
Cash from Investing | 43.90M | 20.92M | 25.36M | 37.37M | -268.31M |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 2.26M | 2.90M | 3.55M | 2.00M | 241.07M |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -38.00K | 0.00 | -214.00K | -48.00K | -- |
Cash from Financing | 2.22M | 2.90M | 3.33M | 1.95M | 241.07M |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 8.26M | -3.14M | 1.32M | 13.22M | -55.83M |